Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pre-clinical Trillium Technologies was acquired for US$2.3 B

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Apr 24, 2023 10:34am

254 Views

Post# 35410298

Pre-clinical Trillium Technologies was acquired for US$2.3 B

I don't have to read some non-expert analytical pulp to see what really is happening in the field of oncology to know what the REAL valuations are for late stage Phase 3 ready platform drug companies.

Unfortunately Canadafan and his supporters are just uninformed parrots of some obscure and gross information produced for the general public's consumption, which has nothing to do with the current state of oncology company valuations.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities